Primary central nervous system lymphoma (PCNSL) risk is greatly increased in immunosuppressed human immunodeficiency virus-infected people. Using data from the US transplant registry linked with 17 cancer registries , we studied PCNSL and systemic non-Hodgkin lymphoma (NHL) in 288 029 solid organ transplant recipients. Transplant recipients had elevated incidence for PCNSL compared with the general population (standardized incidence ratio = 65.1; N = 168), and this elevation was stronger than for systemic NHL (standardized incidence ratio=11.5; N = 2043).
leptomeninges, or spinal cord without evidence of any systemic involvement. 4, 6 Among individuals infected with human immunodeficiency virus (HIV), PCNSL is a condition that marks the onset of acquired immunodeficiency syndrome (AIDS), and its risk is greatly increased in HIV-infected individuals. 7 Few cases of PCNSL have also been reported in patients with primary immunodeficiency disorders, such as Wiskott-Aldrich syndrome and severe combined immunodeficiency disorder. 8 However, data on PCNSL risk in other immunosuppressed populations, such as transplant recipients, are lacking.
PCNSLs are usually aggressive diffuse large B cell lymphomas (DLBCLs), and tumor cells are positive for Epstein-Barr virus (EBV) in more than 90% of the cases, 9,10 which differs from PCNSLs in immunocompetent individuals where EBV-related PCNSL cases are uncommon. 11 The CNS is an immunologically privileged site, and prolonged suppression of T cell-mediated immunity may allow an EBV-driven oncogenic process. 5, 6, 12 PCNSLs often carry a poor prognosis and are associated with high mortality. 4, 10, [13] [14] [15] Treatment for PCNSL in transplant recipients usually includes reducing the dose of immunosuppressive drugs, which may increase the risk of graft failure. 9 Studies on prognosis, however, have been limited by small sample sizes, inclusion of other extranodal NHLs, and absence of evaluation of graft failure as an outcome. [16] [17] [18] [19] Since PCNSL is a rare malignancy, studies in transplant recipients have mostly been descriptive case series. 9, 10, 13, [17] [18] [19] [20] [21] [22] The Transplant
Cancer Match (TCM) Study provides a unique opportunity to study rare cancers that develop in transplant recipients. 2 In this study, we utilized TCM data to describe PCNSL incidence in transplant recipients compared to the general population, evaluate various risk factors for its occurrence, and report on outcomes following PCNSL diagnosis.
We also compare PCNSL with NHLs at other sites to provide insights regarding etiology and prognosis.
| MATERIALS AND METHODS

| Study subjects and ascertainment of NHL
The TCM Study links the US Scientific Registry of Transplant Recipients (SRTR) with population-based cancer registries. 2 The SRTR provides information on all US solid organ transplant recipients beginning in 1987, including demographics, medical characteristics, transplanted organs, and induction and baseline maintenance immunosuppressive medications. Record linkages were completed between the SRTR and 17 cancer registries covering approximately 51% of the US transplant population (see Table 1 note). We included transplant recipients residing in the geographic areas covered by the participating cancer registries, and excluded those who had unknown race/ethnicity (N = 1878), a cancer registry diagnosis of NHL before transplantation (N = 609), or SRTR diagnosis of HIV infection (N = 530). This study was approved by human subjects review committees at the National 
| Statistical analyses
The follow-up began at transplantation or the start of cancer registry coverage (whichever came later), and ended at the earliest of death, graft failure or retransplantation, loss to follow-up, or the last date of cancer registry coverage. We compared incidence of PCNSL and systemic NHL in transplant recipients to the general population using standardized incidence ratios (SIRs), obtained by dividing the tested by introducing interaction terms of PCNSL or systemic NHL diagnosis with follow-up time and was met for all models. We plot Kaplan-Meier survival curves to characterize the probability of death following PCNSL or systemic NHL diagnosis. Some cancer registries did not provide complete information on survival or cancer treatment and were excluded from the relevant survival analyses (see Table 3 and Table S2 notes).
We also ascertained EBV status of the NHL tumors. Cancer registries do not collect this information, but it is collected by the SRTR for PTLD cases. We therefore searched for SRTR records on PTLD and, if available, used the EBV data closest in time to the corresponding matched NHL diagnosis in the cancer registry.
| RESULTS
Among the 288 029 transplants included in the study, the kidney was the most frequently transplanted organ (58.0%), followed by liver (21.7%), heart and/or lung (14.4%), and other/multiple organs (5.9%) ( Table 1 As shown in Table 2 , PCNSL incidence appeared to increase with age but the differences were not significant. PCNSL incidence did not differ by sex, while Asians/Pacific Islanders had 2-fold higher incidence (Table S1 ).
The pattern for systemic NHLs differed from that for PCNSL for some, but not all variables (Table 2 ). Systemic NHL incidence was high in young transplant recipients (age at transplantation, 0-17 years), decreased with increasing age until 35-49 years, and then increased again, with highest incidence in people ≥65 years at transplantation ( Table 2) . Incidence of systemic NHLs was lower among females compared to males, and among non-Hispanic to transplant recipients without any NHL. An elevated risk of these outcomes was also observed after diagnosis of systemic NHLs, but the increase was smaller (Table 3 ). In an analysis that ignored graft failure and continued to follow NHL patients across multiple transplants, recipients with PCNSL had increased risk of death compared to those with systemic NHLs (aHR = 1.48; 95% CI = 1.14-1.92) (Figure 2 ). We further evaluated the receipt of treatment after NHL diagnosis and its effect on survival in an analysis restricted F I G U R E 1 Risk of primary CNS lymphoma and systemic nonHodgkin lymphomas in solid organ transplant recipients, according to time since transplantation. The figure plots the adjusted incidence rate ratios (y-axis) for primary CNS lymphoma and systemic nonHodgkin lymphomas in solid organ transplant recipients according to time since transplantation in years (x-axis). The comparison time period is 0.01 to 0.50 years after transplant, and the rate ratios were estimated at 0.51-1.00, 1.01-1.49, 1.50-2.00, 2.01-3.00, 3.01-5.00, 5.01-10.00, and >10.00 years after transplant. The adjusted incidence rate ratios are from the multivariable model in Table 1 and are plotted at the midpoint of each time interval. CI, confidence interval; CNS, central nervous system; IRR, incidence rate ratio; NHL, non-Hodgkin lymphoma Other/multiple transplants included pancreas, intestine, kidney-heart, kidney-liver, kidney-pancreas, liver-intestine, pancreas-intestine, and pancreasliver-intestine transplants. e This represent the patients' EBV serostatus at the time of transplantation, and not the EBV status of the lymphomas that occurred in the posttransplant period.
T A B L E 2 (Continued)
to registries that provided treatment information (Table S2) 
| DISCUSSION
Solid organ transplant recipients have an increased risk of cancer, including NHLs, largely due to iatrogenic immunosuppression. 2 In a comprehensive analysis of a large cohort of solid organ transplant recipients, we demonstrate that PCNSL incidence is substantially elevated in transplant recipients compared to the general population. We CI, confidence intervals; CNS, central nervous system; HR, hazard ratio; NHL, non-Hodgkin lymphoma a Data from 3 cancer registries were excluded since they provided incomplete information on survival for NHL cases. Hazard ratios were adjusted for age at transplantation, sex, race, organ transplanted, and year of transplantation.
F I G U R E 2 Survival after diagnosis of primary CNS lymphoma or systemic non-Hodgkin lymphomas in solid organ transplant recipients. The figure shows Kaplan-Meier curves that represent the probability of survival after diagnosis of primary CNS lymphoma or systemic non-Hodgkin lymphomas in solid organ transplant recipients. The probability of survival is plotted on the y-axis, while the follow-up time after a diagnosis of the non-Hodgkin lymphomas is depicted on the x-axis. The hazard ratio is adjusted for age at transplantation, sex, race/ethnicity, year of transplantation, and organ transplanted. CI, confidence intervals; CNS, central nervous system; HR, hazard ratio; NHL, non-Hodgkin lymphoma aggressive clinical features. 31 In this study, we found some differences between transplant recipients who developed PCNSL and those with systemic NHL in terms of demographic characteristics, transplanted organs, induction immunosuppression, and time since transplantation, further suggesting that PCNSL and systemic NHL are etiologically distinct entities.
For instance, we did not observe an association between age at transplantation and PCNSL incidence independent of recipients' EBV serostatus, which may be due to the small number of PCNSL cases.
Nonetheless, a distinct pattern was observed for systemic NHL, where the incidence was high in the youngest (0-17 years) and the oldest (65+ years) age groups. Associations between age and NHL risk in transplant recipients have been described previously, 16, 34 and might be related to control of primary EBV infection in children or processes related to aging in older adults. EBV-seronegative transplant recipients have a high risk of acquiring the infection in the posttransplant period. 35, 36 Prolonged immunosuppression and lack of EBV-specific T cell immune responses may lead to unchecked monoclonal expansion of EBV-infected B cells and development of lymphoma. 37 The elevated incidence of PCNSL among EBV-seronegative recipients in this study, and the increase in incidence within 1.5 years following transplant, support the role of primary EBV infection in contributing to PCNSL.
Similar findings have been reported previously for NHLs overall and DLBCL in transplant recipients, 22, 34, [38] [39] [40] although in our study, the pattern for PCNSL incidence according to time since transplantation was stronger than for systemic NHLs.
To some extent, the pattern in PCNSL incidence also reflects the degree of immunosuppression among transplant recipients. The relatively high incidence associated with "other/multiple" organ transplants and low incidence for liver transplants may be due to differences in the intensity of immunosuppressive regimens. Perhaps surprisingly, however, recipients of a heart and/or lung did not have higher PCNSL incidence than kidney recipients, even though they typically receive intensive immunosuppression. Induction immunosuppressive drugs given immediately posttransplant to prevent acute rejection include anti-CD3 monoclonal antibodies (OKT3), alemtuzumab, IL-2 receptor antagonists, and polyclonal antibodies such as anti-thymocyte globulin. 41, 42 We previously reported that alemtuzumab induction was associated with an increased risk of NHL, colorectal cancer, and thyroid cancer among kidney recipients. 43 Herein, we demonstrated that PCNSL risk was increased after induction with alemtuzumab, monoclonal antibodies, and polyclonal antibodies. The incidence of systemic NHL was also increased after alemtuzumab and monoclonal antibodies, but not polyclonal antibodies, although it is unclear why this pattern differs between PCNSL and systemic NHL.
We also showed that Asians/Pacific Islanders had more than twice the incidence of PCNSL compared with non-Hispanic whites, while the incidence of systemic NHL was highest among non-Hispanic whites.
The reason for this difference is unknown. A previous analysis of SEER data found that PCNSL incidence was similar for non-Hispanic whites and Asians/Pacific Islanders in adults over 50 years of age in the US general population (a largely immunocompetent population among whom the prevalence of HIV-infected individuals and transplant recipients is low). 44 Similar analyses for younger individuals in the US population (0-49 years) found a higher PCNSL risk in non-Hispanic blacks, which may be attributed to the higher prevalence of HIV infection in this group. 44, 45 We found that PCNSL increased the risk of death and graft failure/retransplantation in transplant recipients compared to recipients without any NHL. The risk was also increased after systemic NHL, but the magnitude was much lower. Furthermore, when we restricted the analysis to NHL cases, transplant recipients with PCNSL had a 1.5-fold increased risk of dying compared to recipients with systemic NHL. PCNSL has a low 5-year survival rate of 30% in immunocompetent individuals. 15 The 5-year survival rate after PCNSL was similar among transplant recipients in our study as has been reported for immunocompetent individuals, but lower than for recipients with systemic NHL. PCNSL treatment is centered around the use of high-dose methotrexate-based chemotherapy, and whole-brain radiotherapy (considered to be a standard-of-care until the early 1990s) is often used as a salvage therapy. 46 Rituximab, an anti-CD20 monoclonal antibody that has been the mainstay of treatment of systemic NHLs, has poor CNS penetration. 47, 48 Furthermore, patients with renal insufficiency, older age, or poor performance status-factors that are often present in transplant recipients-may not be candidates for high-dose methotrexate therapy and may receive palliative whole-brain radiotherapy or supportive care. 46 Mortality in PCNSL patients may be caused by involvement of the CNS itself, particularly the deep structures within the brain, 49 or delayed neurotoxic effects of therapy.
Although it is a rare malignancy, physicians managing the care of transplant recipients should be aware about this heightened risk, particularly for recipients who are EBV-seronegative at the time of transplant, and those who are treated with alemtuzumab, monoclonal antibodies, or polyclonal antibodies for induction immunosuppression. As some risk factors for PCNSL differ from that of systemic NHL, the possibility of etiologic heterogeneity should be explored in other populations.
The prognosis of PCNSL in transplant recipients is poor, pointing to a need to develop improved therapies for this malignancy. 
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